A Hybrid Effectiveness Implementation Trial Evaluating Behavioral Treatments for Insomnia for Socioeconomically Disadvantaged Adults in Primary Care

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05759065
Collaborator
(none)
350
2
46

Study Details

Study Description

Brief Summary

The overall objective of this study is to conduct a randomized effectiveness-implementation trial to test the non-inferiority of tele-Brief Behavioral Treatment for Insomnia vs. tele-Cognitive-Behavioral Therapy for Insomnia among socioeconomically disadvantaged adults with insomnia in the primary care setting.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Tele-Brief Behavioral Treatment for Insomnia
  • Behavioral: Tele-Cognitive-Behavioral Therapy for Insomnia
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
350 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Hybrid Effectiveness Implementation Trial Evaluating Behavioral Treatments for Insomnia for Socioeconomically Disadvantaged Adults in Primary Care
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2027
Anticipated Study Completion Date :
Jun 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tele-Brief Behavioral Treatment for Insomnia

Behavioral: Tele-Brief Behavioral Treatment for Insomnia
Brief Behavioral Treatment for Insomnia (BBTI) comprises of up to five weekly intervention visits by phone, delivered by a variety of practitioners without formal training in sleep.

Active Comparator: Tele-Cognitive-Behavioral Therapy for Insomnia

Behavioral: Tele-Cognitive-Behavioral Therapy for Insomnia
Cognitive-Behavioral Therapy for Insomnia (CBTI) is a multicomponent strategy delivered by trained mental health clinicians over 6 to 12 weeks.

Outcome Measures

Primary Outcome Measures

  1. Insomnia severity index, ISI [3 months]

    The Insomnia Severity Index is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia in the last month. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Secondary Outcome Measures

  1. Insomnia severity index, ISI [6- and 12-months]

    The Insomnia Severity Index is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia in the last month. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

  2. Quality of Life and Symptoms - Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health [3-months]

    The PROMIS Global Health measures assess an individual's physical, mental and social health. The measure produces two scores: Physical and Mental Health from 4 items each. Item responses are combined to yield a T-score with a population mean of 50 and standard deviation of 10.

  3. Quality of Life and Symptoms - Generic-quality of life [3-months]

    Generic-quality of life will be assessed by the change in the Euroqol - 5 Dimensions (EQ-5D) questionnaire. The questionnaire comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. There is no total score or range.

  4. Generalized Anxiety Disorder (GAD-7) [3-months]

    GAD-7 measures self-reported anxiety disorder. The measure includes 7-items with higher scores indicating anxiety. The minimum score is 0 and the maximum score is 21.

  5. Patient Health Questionnaire for depression (PHQ-8) [3-months]

    PHQ-8 measures self-reported current depression. The measure includes 8-items with higher scores indicating depression. The minimum score is 0 and the maximum score is 24.

  6. Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Impairment, 8a [3-months]

    PROMIS Sleep Impairment measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness during the past seven days. The measure includes 8-items with higher scores indicating greater sleep impairment. The minimum score is 8 and the maximum score 40. Item responses are combined to yield a T-score with a population mean of 50 and standard deviation of 10.

  7. Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance, 8b [3-months]

    PROMIS Sleep Disturbance measures self-reported sleep quality and associated daytime functioning during the past seven days. The measure includes 8-items with higher scores indicating greater sleep disturbance. The minimum score is 8 and the maximum score is 40. Item responses are combined to yield a T-score with a population mean of 50 and standard deviation of 10.

  8. Diary reported sleep duration [3-months]

    Self-reported sleep duration with be measured using sleep diary

  9. Diary-reported sleep efficiency [3-months]

    Self-reported sleep efficiency with be measured using sleep diary

  10. Number of participants with hypnotic use self-reported from the sleep diary [3-months]

    Hypnotic use will be measured by the number of participants who self-reported use on the sleep diary

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Meet clinical diagnostic criteria for insomnia

  • Insomnia severity score > 11

  • Eligible to receive care through publicly supported medical assistance, OR

  • Identify as race or ethnic minority, OR

  • Spanish speaking

Exclusion Criteria:
  • Untreated, current major depressive disorder

  • History of bipolar or psychosis

  • Active substance abuse

  • Seizure within the past 1 year

  • Main sleep period outside of 8pm - 11am

  • Regular nightshift work

  • Untreated, previously diagnosed moderate to severe sleep apnea

  • Severe medical condition, which may require hospitalizations over the next 6 months

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Brigham and Women's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Suzanne M. Bertisch, MD, MPH, Associate Physician, Clinical Director of Behavioral Sleep Medicine, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT05759065
Other Study ID Numbers:
  • 2023P000106
First Posted:
Mar 8, 2023
Last Update Posted:
Mar 14, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 14, 2023